| Primary | Number of Serious Adverse Events Relative to Treatment Group | | | Posted | | Number | | participants | | 28 days | | | | ID | Title | Description |
|---|
| OG000 | GLS-1027 120 mg | One 120 mg pill of GLS-1027 + 2 Placebo pills given by mouth once daily GLS-1027: GLS-1027 is an oral medication with high bioavailability that has IL-6 and IL-1β inhibitory activity. | | OG001 | GLS-1027 360 mg | Three 120 mg pills of GLS-1027 given by mouth once daily GLS-1027: GLS-1027 is an oral medication with high bioavailability that has IL-6 and IL-1β inhibitory activity. | | OG002 | Placebo | Three Placebo pills given by mouth once daily Placebo: Placebo looks like GLS-1027 |
| | | Title | Denominators | Categories |
|---|
| | |
| |
| Primary | Number of Treatment Failures at Day 28 From Enrollment | | | Posted | | Number | | participants | | 28 days | | | | ID | Title | Description |
|---|
| OG000 | GLS-1027 120 mg | One 120 mg pill of GLS-1027 + 2 Placebo pills given by mouth once daily GLS-1027: GLS-1027 is an oral medication with high bioavailability that has IL-6 and IL-1β inhibitory activity. | | OG001 | GLS-1027 360 mg | Three 120 mg pills of GLS-1027 given by mouth once daily GLS-1027: GLS-1027 is an oral medication with high bioavailability that has IL-6 and IL-1β inhibitory activity. | | OG002 | Placebo | Three Placebo pills given by mouth once daily Placebo: Placebo looks like GLS-1027 |
| |
| Secondary | Assess the Number of Days of Hospitalization Relative to Treatment Group | | | Posted | | Mean | Standard Deviation | days | | 28 days | | | | ID | Title | Description |
|---|
| OG000 | GLS-1027 120 mg | One 120 mg pill of GLS-1027 + 2 Placebo pills given by mouth once daily GLS-1027: GLS-1027 is an oral medication with high bioavailability that has IL-6 and IL-1β inhibitory activity. | | OG001 | GLS-1027 360 mg | Three 120 mg pills of GLS-1027 given by mouth once daily GLS-1027: GLS-1027 is an oral medication with high bioavailability that has IL-6 and IL-1β inhibitory activity. | | OG002 | Placebo | Three Placebo pills given by mouth once daily Placebo: Placebo looks like GLS-1027 |
| |
| Secondary | Assess the Number of Days Requiring ICU Care Relative to Treatment Group | | | Posted | | Mean | Inter-Quartile Range | Days ICU care | | 28 days | | | | ID | Title | Description |
|---|
| OG000 | GLS-1027 120 mg | One 120 mg pill of GLS-1027 + 2 Placebo pills given by mouth once daily GLS-1027: GLS-1027 is an oral medication with high bioavailability that has IL-6 and IL-1β inhibitory activity. | | OG001 | GLS-1027 360 mg | Three 120 mg pills of GLS-1027 given by mouth once daily GLS-1027: GLS-1027 is an oral medication with high bioavailability that has IL-6 and IL-1β inhibitory activity. | | OG002 | Placebo | Three Placebo pills given by mouth once daily Placebo: Placebo looks like GLS-1027 |
| |
| Secondary | Assess the Number of Days of NIV, High-flow O2, or Mechanical Ventilation Relative to Treatment Group | | | Posted | | Mean | Standard Deviation | days | | 28 days | | | | ID | Title | Description |
|---|
| OG000 | GLS-1027 120 mg | One 120 mg pill of GLS-1027 + 2 Placebo pills given by mouth once daily GLS-1027: GLS-1027 is an oral medication with high bioavailability that has IL-6 and IL-1β inhibitory activity. | | OG001 | GLS-1027 360 mg | Three 120 mg pills of GLS-1027 given by mouth once daily GLS-1027: GLS-1027 is an oral medication with high bioavailability that has IL-6 and IL-1β inhibitory activity. | | OG002 | Placebo | Three Placebo pills given by mouth once daily Placebo: Placebo looks like GLS-1027 |
| |
| Secondary | Assess the Maximal Level of Positive End-Expiratory Pressure (PEEP) for Subjects Who Are Intubated Relative to Treatment Group. | | | Posted | | Mean | Inter-Quartile Range | cm H2O | | 28 days | | | | ID | Title | Description |
|---|
| OG000 | GLS-1027 120 mg | One 120 mg pill of GLS-1027 + 2 Placebo pills given by mouth once daily GLS-1027: GLS-1027 is an oral medication with high bioavailability that has IL-6 and IL-1β inhibitory activity. | | OG001 | GLS-1027 360 mg | Three 120 mg pills of GLS-1027 given by mouth once daily GLS-1027: GLS-1027 is an oral medication with high bioavailability that has IL-6 and IL-1β inhibitory activity. | | OG002 | Placebo | Three Placebo pills given by mouth once daily Placebo: Placebo looks like GLS-1027 |
| |
| Secondary | Assess the Number of Days of PEEP > 5 cm H2O for Subjects Who Are Intubated Relative to Treatment Group | | | Posted | | Mean | Inter-Quartile Range | Days intubated PEEP > 5 cm H2O | | 28 days | | | | ID | Title | Description |
|---|
| OG000 | GLS-1027 120 mg | One 120 mg pill of GLS-1027 + 2 Placebo pills given by mouth once daily GLS-1027: GLS-1027 is an oral medication with high bioavailability that has IL-6 and IL-1β inhibitory activity. | | OG001 | GLS-1027 360 mg | Three 120 mg pills of GLS-1027 given by mouth once daily GLS-1027: GLS-1027 is an oral medication with high bioavailability that has IL-6 and IL-1β inhibitory activity. | | OG002 | Placebo | Three Placebo pills given by mouth once daily Placebo: Placebo looks like GLS-1027 |
| |